Michele Green is an internationally renowned board-certified dermatologist with over 2.5 decades of experience providing her patients with the best non-invasive treatment options
To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
Glucocorticoid impaired the wound healing ability of endothelial progenitor cells by reducing the expression of CXCR4 in the PGE2 pathway
In laboratory experiments, the researchers exposed ovarian fibroblasts to IL-11
In 2026, more than 12% of American adults are taking these medications, the US obesity rate has declined from its 2022 peak, and the global market has surpassed $132 billion
[Abstract]2019 Nov;30(11):1419-1430
